Most people process dietary fructose without a second thought — the sugar passes through the intestinal wall, enters the liver, and is phosphorylated by fructokinase into fructose-1-phosphate (Fru1P). One enzyme then stands between Fru1P and the rest of metabolism: aldolase B¹¹ aldolase B
encoded by the ALDOB gene on chromosome 9q22.3; the liver-specific isoform that cleaves fructose-1-phosphate into glyceraldehyde and dihydroxyacetone phosphate for entry into glycolysis and gluconeogenesis. When aldolase B fails, Fru1P cannot be cleared. It accumulates rapidly in liver and kidney cells every time fructose is consumed, setting off a cascade of metabolic disruption. The condition that results is hereditary fructose intolerance²² hereditary fructose intolerance
an autosomal recessive inborn error of metabolism caused by biallelic pathogenic variants in ALDOB; distinct from benign fructosuria and dietary fructose sensitivity.

The Y204X variant (rs370793608) introduces a premature stop codon at tyrosine 204 of the aldolase B protein, producing a severely truncated, non-functional enzyme. It is listed as Pathogenic in ClinVar³³ Pathogenic in ClinVar
VCV000632627, 2-star classification from multiple independent laboratory submitters including LabCorp Genetics and Baylor Genetics. This variant is extremely rare globally (alternate allele frequency ~1 in 100,000 alleles in population databases), consistent with a severe disease-causing allele subject to strong purifying selection.

The Mechanism

Fru1P accumulation is the central pathological event in HFI. Cellular Fru1P acts as a competitive inhibitor of the remaining glycolytic aldolase isoforms (aldolase A and C), amplifying its own toxic effect. Two parallel consequences follow: first, intracellular phosphate is sequestered in Fru1P, depleting free phosphate and ATP, which impairs glycogenolysis, gluconeogenesis, and energy production — causing the characteristic post-fructose hypoglycemia⁴⁴ first, intracellular phosphate is sequestered in Fru1P, depleting free phosphate and ATP, which impairs glycogenolysis, gluconeogenesis, and energy production — causing the characteristic post-fructose hypoglycemia
Buziau AM et al. Recent advances in the pathogenesis of HFI. Cell Mol Life Sci, 2020. Second, elevated Fru1P disrupts N-linked glycosylation pathways in the hepatocyte, contributing to chronic liver injury and fat accumulation.

The premature stop at position 204 (of 364 amino acids) results in either a severely truncated protein or, more likely, nonsense-mediated mRNA decay — meaning no functional enzyme is produced from this allele at all. The Y204X truncation removes the entire C-terminal catalytic domain of aldolase B, making this a complete loss-of-function allele. A single pathogenic allele (carrier state) is sufficient to flag reproductive risk, but clinical HFI requires biallelic disruption — either homozygous Y204X or compound heterozygosity with a second pathogenic ALDOB allele.

The Evidence

HFI is rare — the largest population prevalence study in Central Europe estimated 1:26,100⁵⁵ estimated 1:26,100, though the true prevalence may be higher due to under-diagnosis in individuals who learn to avoid sweet foods by experience. Three mutations dominate the ALDOB allele spectrum in European patients: p.A150P (64%), p.A175D (16%), and p.N335K (8%)⁶⁶ p.A150P (64%), p.A175D (16%), and p.N335K (8%)
Davit-Spraul A et al. Mol Genet Metab, 2008. Y204X is a rare variant accounting for a small fraction of pathogenic alleles, identified in Central European and likely other European family cohorts.

The clinical picture of untreated HFI in an affected individual (two non-functional ALDOB copies) is well documented: fructose ingestion triggers nausea, vomiting, abdominal pain, and sweating within 20–30 minutes. Recurrent exposure causes progressive liver and kidney damage — progressing to hepatomegaly, renal tubular acidosis, growth retardation, and in severe cases liver failure. Affected individuals characteristically develop an aversion to sweet foods and fruit, often unknowingly self-protecting before diagnosis.

Even among adherent patients, a study of 48 HFI patients over 10 years found that mean daily fructose intake of 169 mg (unavoidable trace amounts) correlated with abnormal carbohydrate-deficient transferrin glycosylation markers, indicating that even minimal ongoing exposure has measurable biochemical consequences⁷⁷ mean daily fructose intake of 169 mg (unavoidable trace amounts) correlated with abnormal carbohydrate-deficient transferrin glycosylation markers, indicating that even minimal ongoing exposure has measurable biochemical consequences
Di Dato F et al. Nutrients, 2019.

Dietary restriction of all fructose, sucrose, and sorbitol — the three molecules that yield fructose-1-phosphate — completely prevents symptoms and allows normal organ function. Long-term adherent patients have normal life expectancy and quality of life⁸⁸ normal life expectancy and quality of life
Singh SK, Sarma MS. World J Clin Pediatr, 2022.

Practical Actions

For biallelic carriers (affected individuals), the foundation of management is strict, lifelong avoidance of fructose, sucrose, sorbitol, and their derivatives. This requires label-reading expertise: sucrose (table sugar) hydrolyzes to glucose + fructose; sorbitol is oxidized to fructose intracellularly; high-fructose corn syrup, honey, agave, fruit juices, and many medications use these sugars. Vitamin C supplementation is specifically needed because the restriction removes most fruit sources — studies show that 30% of non-supplemented HFI patients develop vitamin C deficiency⁹⁹ 30% of non-supplemented HFI patients develop vitamin C deficiency
Cano A et al. Eur J Clin Nutr, 2022.

For heterozygous carriers (one Y204X allele), full enzyme function is maintained with a single functional ALDOB copy. The primary concern is reproductive: a carrier who reproduces with another ALDOB carrier (of any pathogenic allele) faces a 25% probability per pregnancy of an affected child. The three most common European ALDOB alleles (A150P, A175D, N335K) account for ~84% of pathogenic alleles and can be tested for on a targeted panel.

Interactions

The most important interaction for this variant is compound heterozygosity with other pathogenic ALDOB alleles. Because Y204X is a complete loss-of-function allele, any second pathogenic ALDOB allele in trans will result in clinical HFI. The three common European alleles (p.A150P rs45436095, p.A175D rs78654866, p.N335K rs28936415) are the most likely compound heterozygous partners for Y204X in European-ancestry individuals. Carrier partners of Y204X carriers should be offered targeted ALDOB panel testing that includes these three common alleles plus sequencing of the entire coding region.

Statins are among the most prescribed drugs in the world, yet up to half of patients do not achieve their LDL-cholesterol target on standard doses. Much of this variability traces back to the gene statins are designed to inhibit: HMGCR¹¹ HMGCR
3-hydroxy-3-methylglutaryl-CoA reductase — the enzyme that catalyses the rate-limiting step in the mevalonate pathway, which produces cholesterol and other critical lipids in every cell of the body. The rs3846662 variant sits in intron 13 of HMGCR and influences a molecular editing process that determines how much drug-sensitive enzyme your body actually makes.

The Mechanism

HMGCR pre-mRNA can be spliced two ways. The dominant product is the full-length 888-amino-acid enzyme — the form that statins inhibit. The alternative product, known as HMGCR Δ13 or HMGCR13(-)²² HMGCR Δ13 or HMGCR13(-)
A shorter isoform in which the 24-amino-acid stretch encoded by exon 13 is excluded. This region overlaps the statin-binding domain of the enzyme, lacks the segment of the catalytic domain where statins dock. The Δ13 form retains partial enzymatic activity but is substantially less sensitive to statin inhibition.

rs3846662 sits within the intron 13 branch-point region and controls the ratio of full-length to Δ13 transcript. Yu et al. 2014³³ Yu et al. 2014
Yu CY et al. HNRNPA1 regulates HMGCR alternative splicing and modulates cellular cholesterol metabolism. Hum Mol Genet, 2014 demonstrated that the RNA-binding protein HNRNPA1 preferentially binds the A allele at this position and promotes exon 13 skipping: cells with the A allele produce a higher fraction of Δ13 mRNA. Consistent with this, AA homozygotes have the highest Δ13 ratio and the most attenuated statin response, while GG homozygotes maintain a predominantly full-length transcript and better statin sensitivity.

Medina & Krauss 2009⁴⁴ Medina & Krauss 2009
Medina MW, Krauss RM. The role of HMGCR alternative splicing in statin efficacy. Trends Cardiovasc Med, 2009 proposed that the Δ13 protein forms inactive heterodimers with full-length HMGCR, further diluting the pool of drug-accessible enzyme beyond what the mRNA ratio alone would predict.

The Evidence

The clinical link was established by Medina et al. 2008⁵⁵ Medina et al. 2008
Medina MW et al. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma LDL cholesterol response to simvastatin. Circulation, 2008 in 170 lymphoblastoid cell lines from the Cholesterol and Pharmacogenetics (CAP) study. Greater Δ13 expression was inversely correlated (p≤0.0001) with in vivo reductions of total cholesterol, LDL-C, apoB, and triglycerides, with the splicing ratio explaining 6–15% of the variation in statin response — a sizeable fraction given the many factors involved.

Leduc et al. 2016⁶⁶ Leduc et al. 2016
Leduc V et al. Role of rs3846662 and HMGCR alternative splicing in statin efficacy and baseline lipid levels in familial hypercholesterolemia. Pharmacogenet Genomics, 2016 studied 37 French-Canadian familial hypercholesterolaemia patients and found that women with the AA genotype achieved a significantly smaller LDL-C reduction on statin therapy (38.4% vs 46.2%, p<0.05) compared with G carriers. Strikingly, alternative splicing explained 22–55% of the variance in statin response in this cohort. The sex-specific finding was notable: men showed similar splicing ratios but no detectable difference in statin response — likely reflecting oestrogen-dependent regulation of HMGCR expression that amplifies splicing effects in women.

Cano-Corres et al. 2018⁷⁷ Cano-Corres et al. 2018
Cano-Corres R et al. Influence of 6 genetic variants on the efficacy of statins in patients with dyslipidaemia. J Clin Lab Analysis, 2018 confirmed in 100 patients that G allele carriers showed significantly lower reduction in total cholesterol and non-HDL-C and were less likely to reach therapeutic cholesterol targets. Note that this study found the G allele direction — reflecting complex population-specific interactions between baseline lipid levels and splicing efficiency that remain under active investigation.

Practical Actions

For individuals with the AA or AG genotype, statin dose optimisation and closer monitoring of LDL-C response are warranted. If standard statin doses do not achieve LDL targets, the rs3846662 genotype provides a pharmacogenomic rationale for dose escalation, statin switching, or the addition of non-statin agents such as ezetimibe (which inhibits intestinal cholesterol absorption via a completely independent mechanism unaffected by HMGCR splicing).

Plant sterols and stanols (2 g/day from fortified foods or supplements) competitively inhibit dietary cholesterol absorption and can reduce LDL-C by 8–10% independently of the mevalonate pathway — making them a useful adjunct specifically when HMGCR is less statin-sensitive.

Interactions

This variant interacts with APOE genotype. Leduc et al. 2016 noted that the AA genotype at rs3846662 was associated with elevated baseline total and LDL-cholesterol specifically in individuals without APOE4 (rs429358 CC genotype), suggesting the two loci have partially overlapping effects on lipid setpoint and statin response.

Other HMGCR coding variants — rs17238540 and rs17244841 (both associated with statin response in the WOSCOPS trial) — are in partial linkage disequilibrium with rs3846662 and may tag the same underlying splicing haplotype. Interaction with rs7703051 (another HMGCR intron variant) has also been proposed in the literature.

Riboflavin (vitamin B2) is the molecular precursor to FAD and FMN¹¹ FAD and FMN
Flavin adenine dinucleotide and flavin mononucleotide — the two active coenzyme forms of riboflavin that serve as electron carriers in over 100 cellular oxidoreduction reactions, including the mitochondrial electron transport chain, fatty acid oxidation, and amino acid metabolism. Unlike many vitamins that diffuse freely across cell membranes, riboflavin is a polar molecule that cannot enter most cells without help. The brain and peripheral nervous system are especially dependent on dedicated transport proteins to maintain adequate intracellular riboflavin. The SLC52A2 gene encodes one of those proteins — RFVT2 (riboflavin transporter 2), the principal riboflavin transporter expressed in neurons and intestinal epithelium.

When SLC52A2 is non-functional, riboflavin cannot enter nerve cells efficiently, FAD and FMN are depleted, and neuronal energy metabolism collapses. The clinical consequence is Brown-Vialetto-Van Laere syndrome type 2²² Brown-Vialetto-Van Laere syndrome type 2
BVVLS2 (OMIM #614707) — named for the three clinicians who independently described the phenotype between 1894 and 1959. The molecular cause was not identified until 2010 when mutations in SLC52A3 were found; SLC52A2 was implicated in 2012. (BVVLS2), a rare progressive neuronopathy with sensorineural deafness, bulbar palsy, and respiratory compromise that is fatal without treatment. Crucially, it is one of very few inherited neurodegenerative disorders that responds dramatically to supplementation.

The Mechanism

The c.368T>C variant substitutes a leucine for a proline at position 123 of the RFVT2 protein (p.Leu123Pro). Proline is structurally unique — its side chain loops back to form a ring with the backbone nitrogen, introducing rigidity and a kink into a polypeptide chain. Replacing a flexible leucine with proline at position 123 disrupts the local fold of the transmembrane domain.

Functional transport assays³³ Functional transport assays
Haack TB et al. Impaired riboflavin transport due to missense mutations in SLC52A2 causes Brown-Vialetto-Van Laere syndrome. J Inherit Metab Dis, 2012 demonstrated that cells overexpressing the p.Leu123Pro mutant showed significantly reduced [³H]riboflavin uptake compared to wild-type RFVT2, confirming that the structural change directly impairs transport activity. The same study also identified p.Leu339Pro in the same patient as a compound heterozygous partner, illustrating the typical presentation: most BVVLS2 patients carry two different pathogenic SLC52A2 alleles rather than two identical ones.

The Evidence

BVVLS2 is rare but the treatment response is among the most striking in all of metabolic genetics. Foley et al. 2014⁴⁴ Foley et al. 2014
Foley AR et al. Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2. Brain, 2014 described 18 patients from 13 families with SLC52A2 mutations, demonstrating "significant and sustained clinical and biochemical improvements" with high-dose oral riboflavin, including improvements in motor function, respiratory capacity, and acylcarnitine profiles in 10 of 13 patients with preliminary data.

The natural history data makes the treatment case starkly. Bosch et al. 2012⁵⁵ Bosch et al. 2012
Bosch AM et al. The Brown-Vialetto-Van Laere and Fazio Londe syndrome revisited: natural history, genetics, treatment and future perspectives. Orphanet J Rare Dis, 2012 reviewed 74 BVVLS and Fazio-Londe patients across all published cases: all 13 riboflavin-treated patients survived, while 28 of 61 untreated patients died — most before age 4 if onset was in infancy. Without treatment, children typically progress to ventilator dependence.

The standard dosing is established by clinical practice: Cali et al. GeneReviews 2015⁶⁶ Cali et al. GeneReviews 2015
Cali E et al. Riboflavin Transporter Deficiency. GeneReviews, University of Washington, 2015 (updated 2021) specifies 10–50 mg/kg/day of oral riboflavin for riboflavin transporter deficiency, with early initiation producing substantially better outcomes than late treatment.

ClinVar lists this variant (VCV000039576) as pathogenic for Brown-Vialetto-Van Laere syndrome 2 with five independent submitters including Cambridge Genomics Laboratory, OMIM, PreventionGenetics, and the Solve-RD Consortium.

Practical Actions

Because BVVLS2 is autosomal recessive, a single heterozygous copy of the p.Leu123Pro variant does not cause disease. Heterozygous carriers have one functional RFVT2 allele, which is sufficient for normal riboflavin transport under typical conditions. The clinical significance of carrier status is primarily reproductive: if both parents carry pathogenic SLC52A2 variants, each child has a 25% chance of inheriting biallelic mutations and developing BVVLS2.

For homozygous or compound heterozygous individuals, high-dose riboflavin is the only established disease-modifying treatment. It must be started immediately and continued lifelong — riboflavin supplementation does not cure the underlying transporter defect but compensates for it by driving passive diffusion through mass action. Sensorineural hearing loss, once established, is typically not recovered with treatment even when motor and respiratory function improve.

Interactions

Compound heterozygosity is the rule in BVVLS2: most patients carry p.Leu123Pro on one chromosome and a different pathogenic SLC52A2 variant on the other. The related gene SLC52A3 (RFVT3) causes BVVLS type 3 with an overlapping phenotype; both conditions respond to riboflavin. SLC52A1 (RFVT1) causes Fazio-Londe syndrome. When a patient presents with bulbar palsy and hearing loss, all three SLC52A genes should be sequenced to determine the causative gene, as the treatment (riboflavin) is the same for all three.

Every heartbeat begins at the sarcomere — the basic contractile unit of cardiac muscle, where the protein beta-myosin heavy chain¹¹ beta-myosin heavy chain
the primary motor protein of the heart, encoded by MYH7, that generates the forceful contraction driving blood into the aorta with each beat physically pulls actin filaments to shorten the cell. The Arg663Cys variant introduces a single amino acid change in the myosin motor domain — the globular head where the force-generating power stroke occurs — substituting the positively charged arginine at position 663 with a neutral cysteine that is also capable of forming disulfide bonds. ClinVar classifies this as Pathogenic/Likely Pathogenic²² Pathogenic/Likely Pathogenic
VCV000042874, criteria provided, 16 of 22 submitting laboratories concur, no conflicts, and it is essentially absent from gnomAD's population database of over 700,000 sequenced individuals, consistent with a rare, high-penetrance disease allele.

The Mechanism

Codon 663 is situated in the myosin S1 (motor) domain³³ myosin S1 (motor) domain
the ATPase-active globular head region that forms cross-bridges with actin and undergoes the conformational power stroke during muscle contraction. Arginine-663 is highly conserved across vertebrate species⁴⁴ highly conserved across vertebrate species
evolutionary conservation of a residue indicates structural or functional importance; its replacement in any vertebrate species produces disease, underscoring its critical role in myosin function. The substitution of arginine (positively charged, guanidinium side chain) with cysteine (neutral, thiol side chain) is a charge-altering change — the same category of mutation that Watkins et al. (1992)⁵⁵ Watkins et al. (1992) established as prognostically severe in familial HCM, associated with markedly reduced survival compared to charge-neutral variants.

The pathogenic mechanism is dominant-negative: the mutant MYH7 protein is synthesised from the one mutant allele and incorporated into sarcomeres alongside normal protein from the intact allele. Because sarcomeres assemble from mixtures of normal and mutant myosin, even one copy of the variant disrupts cross-bridge kinetics across the entire myofibril. Direct measurement in human HCM myocardium confirms that MYH7 mutations reduce maximum sarcomere force to 73 kN/m² versus 113 kN/m² in donor controls⁶⁶ MYH7 mutations reduce maximum sarcomere force to 73 kN/m² versus 113 kN/m² in donor controls
a 35% reduction in force-generating capacity despite near-normal myofibril density, indicating intrinsic sarcomeric dysfunction rather than structural remodelling alone. Downstream, abnormal calcium handling compounds the defect: iPSC-derived cardiomyocytes from carriers of the closely related Arg663His variant⁷⁷ Arg663His variant
a different amino acid substitution at the identical codon 663, also classified as pathogenic for HCM, rs371898076 showed elevated intracellular calcium, cellular enlargement, and contractile arrhythmia — phenotypes prevented by calcium channel inhibition. The combined effect of impaired force generation and disturbed calcium signalling drives progressive pathological hypertrophy, myocyte disarray, and interstitial fibrosis over years to decades.

The Evidence

The variant's pathogenicity rests on multiple independent lines of evidence evaluated by the ClinGen Inherited Cardiomyopathy Expert Panel⁸⁸ ClinGen Inherited Cardiomyopathy Expert Panel, which adapted the ACMG/AMP classification framework specifically for MYH7. Key criteria include: PS4 (identified in more than 15 unrelated HCM-affected individuals), PM1 (location in the motor domain mutational hotspot), PM5 (other pathogenic changes at the same codon — Arg663His and Arg663Ser), and PM2 (absent from population databases). No population controls in gnomAD carry the A allele at the relevant frequency in any ancestry group (observed count: 3 out of 1,401,470 alleles, frequency 0.0000021).

Among all sarcomeric HCM mutations, MYH7 pathogenic variants are associated with particularly adverse outcomes⁹⁹ MYH7 pathogenic variants are associated with particularly adverse outcomes. In a Chinese cohort of 52 MYH7 mutation carriers compared to 18 MYBPC3 carriers, MYH7 patients had seven sudden cardiac deaths versus zero in the MYBPC3 group, and mean survival was 45 years versus 73 years — a 28-year reduction. Van Driest et al. (2004)¹⁰¹⁰ Van Driest et al. (2004) found MYH7 mutation carriers present with HCM nearly a decade earlier than sarcomere-negative patients (mean 33 vs 43 years), have substantially greater left ventricular wall thickness, and undergo myectomy at twice the rate.

The 1992 founding observation by Watkins et al.¹¹¹¹ Watkins et al. remains instructive: charge-altering arginine substitutions in MYH7 — the precise category that includes Arg663Cys — were associated with mean age at death of 33 years, versus near-normal survival for charge-neutral substitutions. Arg663Cys replaces a charged arginine with a neutral cysteine, placing it squarely in this high-risk mutation class.

Practical Actions

For a carrier of the Arg663Cys variant, the clinical priority is structured cardiac surveillance starting at the time of genetic diagnosis, before symptoms appear. Transthoracic echocardiography establishes whether hypertrophy is already present and quantifies the resting and provoked left ventricular outflow tract (LVOT) gradient — the key determinant of obstructive physiology requiring intervention. Cardiac MRI adds late gadolinium enhancement (LGE) mapping of myocardial fibrosis, which independently predicts sudden death risk beyond conventional HCM risk factors.

Sudden cardiac death (SCD) risk stratification is the most consequential early decision. Current ESC guidelines apply the HCM Risk-SCD calculator to estimate 5-year SCD probability; an ICD (implantable cardioverter-defibrillator) is recommended for estimated risk ≥6%, and is considered for risk 4–6%. Carrying a pathogenic MYH7 variant — particularly one in the charge-altering category — is itself a clinical marker of higher severity that cardiologists incorporate into the risk assessment.

Obstructive HCM (gradient ≥30 mmHg) responds to medical therapy with beta-blockers or disopyramide. Refractory obstruction may require septal reduction (surgical myectomy or alcohol septal ablation). Mavacamten — a first-in-class cardiac myosin inhibitor approved by the FDA for obstructive HCM — directly addresses the hypercontractile mechanism of sarcomere mutations and is an important option for carriers who develop symptomatic obstruction.

Strenuous competitive sport is contraindicated until formal HCM evaluation is complete, given the risk of arrhythmia-triggered SCD during extreme exertion.

Interactions

Codon 663 is a mutational hotspot¹²¹² mutational hotspot
three independent pathogenic substitutions at the same codon — Arg663His (rs371898076), Arg663Cys (this variant), and Arg663Ser — have all been classified as pathogenic or likely pathogenic for HCM in separate individuals and families. A carrier of Arg663Cys could theoretically also carry a second sarcomeric HCM mutation in MYBPC3, TNNT2, TNNI3, or another MYH7 variant; double sarcomeric mutation carriers have been shown in clinical cohorts to face markedly elevated risk of end-stage heart failure and malignant arrhythmias compared to single-variant carriers. Comprehensive sarcomere gene panel testing at the time of diagnosis will detect compound genotypes that substantially alter prognosis and management. If a second sarcomeric variant is found, the management threshold for ICD implantation and specialist referral should be reviewed with a cardiology team experienced in high-risk HCM.

Plasminogen is a liver-secreted zymogen that circulates in the blood and anchors to cell surfaces, fibrin clots, and invading pathogens. When activated by tissue plasminogen activator (tPA) or urokinase (uPA)¹¹ tissue plasminogen activator (tPA) or urokinase (uPA)
serine proteases that convert inactive plasminogen into the active enzyme plasmin, it becomes plasmin — a broad-spectrum protease that dissolves fibrin clots, clears damaged extracellular matrix, recruits macrophages, and helps the immune system track down and destroy pathogens. Rs4252130 tags a haplotype in the PLG gene region that subtly lowers plasminogen output, compressing every downstream function that depends on adequate plasmin activity.

The Mechanism

Rs4252130 (c.1587+155A>C) sits 155 base pairs into an intron of PLG on chromosome 6q26. The PLG gene is on the plus strand, so the alleles reported by genome files match the coding strand directly. The C allele is the variant form, present in about 29% of Europeans but nearly absent in East Asians (under 0.2%). This striking population stratification pattern is typical of regulatory haplotypes under positive or balancing selection²² positive or balancing selection. Though the intronic position itself may not be the causal site, it tags a regional LD block that includes multiple PLG variants associated with reduced plasma plasminogen levels and altered gene expression in liver and osteoblasts. The precise molecular mechanism — whether altered enhancer activity, splicing regulation, or transcription factor binding — has not been characterised for this specific position.

The Evidence

A GWAS of 3,456 healthy individuals³³ A GWAS of 3,456 healthy individuals identified the PLG locus on chr6q26 as the primary genetic determinant of plasma plasminogen levels, with 9 of 11 genome-wide significant SNPs clustering near PLG or the adjacent LPA gene. The lead missense variant (rs4252129, R523W) reduces levels by 13.4% per allele, and adjacent intronic variants in LD tag the same haplotype. Heritability of plasminogen levels was estimated at 48–60%, with identified variants collectively explaining 6.8%.

Schaefer et al. 2015⁴⁴ Schaefer et al. 2015 identified PLG intronic variant rs4252120 — a near neighbour of rs4252130 with identical population allele frequency profiles — as significantly associated with aggressive periodontitis (OR 1.27, p=5.9×10⁻⁵) and shared genetic risk with coronary artery disease, implicating the PLG haplotype in both mucosal immunity and vascular biology.

Munz et al. 2017⁵⁵ Munz et al. 2017 refined the genetic signal downstream of PLG, finding rs1247559 associated with aggressive periodontitis (OR 1.33) and chronic periodontitis (OR 1.15), while also serving as an eQTL for PLG expression in osteoblasts (p=6.9×10⁻⁵). A landmark Science paper (Silva et al. 2021)⁶⁶ Science paper (Silva et al. 2021) demonstrated the causal mechanism: when plasmin-mediated fibrinolysis fails, fibrin accumulates at mucosal surfaces, aberrantly activates neutrophils through αMβ2 integrin, and triggers destructive NET formation and oxidative bursts. PLG polymorphisms from the D-ARIC cohort were associated with common periodontal disease through this pathway.

Beyond periodontitis, plasminogen-deficient mice show 60–90% reductions in macrophage phagocytosis of apoptotic cells Ploplis & Castellino 2014⁷⁷ Ploplis & Castellino 2014, and plasmin is required for macrophage polarization from pro-inflammatory (M1) to resolution-phase (M2) phenotypes Heissig et al. 2020⁸⁸ Heissig et al. 2020.

Practical Actions

Carriers of one or two C alleles have modestly reduced plasminogen-driven fibrinolysis and macrophage function. This does not produce disease on its own but shifts the immune baseline toward less efficient mucosal clearance and wound resolution. The most actionable implications are in periodontal health maintenance and monitoring for conditions where fibrinolytic clearance matters — respiratory, mucosal, and wound-healing contexts.

Interactions

Interaction with the pathogenic PLG variant rs73015965⁹⁹ rs73015965 (K38E, p.Lys38Glu) is possible in principle: a compound heterozygote carrying one severely reduced-activity K38E allele and one expression-reducing haplotype (tagged by rs4252130) would have lower total plasmin activity than either variant alone. This would be expected to increase risk for ligneous periodontitis or mucous membrane complications beyond what either variant predicts independently. However, direct empirical data on this specific combination are lacking.

The PLG region also interacts with LPA (lipoprotein-a): the LPA gene, immediately adjacent on 6q26, affects both plasminogen activation and cardiovascular risk. Carriers of C alleles at rs4252130 who also carry high-Lp(a) alleles at LPA may have compounded vascular risk through impaired fibrinolysis alongside elevated Lp(a).

Deep inside brain neurons and astrocytes, a cytochrome P450 enzyme quietly shapes the chemical environment that governs anxiety, mood, and stress resilience. The CYP7B1 gene¹¹ CYP7B1 gene
Cytochrome P450 family 7 subfamily B member 1; an oxysterol and neurosteroid 7α-hydroxylase expressed prominently in brain, testis, and ovary encodes the enzyme responsible for breaking down two pivotal neurosteroids — DHEA²² DHEA
Dehydroepiandrosterone; the most abundant circulating adrenal steroid, a precursor to both androgens and estrogens and a potent neuromodulator in its own right and pregnenolone — in the brain. By controlling how quickly these substrates are catabolized, CYP7B1 activity sets the local concentration of neurosteroids available for downstream conversion into allopregnanolone³³ allopregnanolone
A potent positive allosteric modulator of GABA-A receptors; the active ingredient of brexanolone (Zulresso) and zuranolone (Zurzuvae), both FDA-approved for postpartum depression, the brain's own benzodiazepine-like molecule. The rs4395923 intronic variant in CYP7B1 was identified as a signal in the anxiety GWAS literature, consistent with the gene's role as a master regulator of GABAergic neurosteroid tone.

The Mechanism

CYP7B1 catalyzes 7α-hydroxylation⁴⁴ CYP7B1 catalyzes 7α-hydroxylation
The addition of a hydroxyl group at the 7α carbon position; this converts the neurosteroid into a less active trihydroxy metabolite that cannot modulate GABA-A receptors of DHEA (Km ~14 μM) and pregnenolone (Km ~4 μM) in the brain. Both substrates are precursors to allopregnanolone⁵⁵ allopregnanolone
Also called 3α,5α-THP (tetrahydroprogesterone); enhances GABA-A receptor chloride conductance via both synaptic and extrasynaptic receptor subtypes, producing tonic inhibition through the steroidogenic cascade. When CYP7B1 activity is lower — whether due to reduced expression or a regulatory variant like rs4395923 — more substrate is available for conversion to these GABAergic neurosteroids. Conversely, higher CYP7B1 activity depletes the neurosteroid pool, reducing GABAergic tone and potentially tipping the excitatory/inhibitory balance toward anxiety-like states.

The enzyme is expressed most abundantly in the hippocampus⁶⁶ hippocampus
The brain region central to memory consolidation, spatial navigation, and stress-response regulation; CYP7B1 mRNA is higher here than in cortex, cerebellum, or other brain regions across multiple primate species, including humans. This regional specificity is clinically meaningful: the hippocampus is a key node in the anxiety circuit, and CYP7B1 expression there is approximately 50% lower in Alzheimer's disease compared to controls. Estrogen further modulates this system through estrogen receptor β, which suppresses CYP7B1-mediated DHEA catabolism in astrocytes, effectively raising local neurosteroid concentrations and contributing to estrogen's neuroprotective effects.

The intronic rs4395923 variant likely influences CYP7B1 expression levels through cis-regulatory effects — consistent with how most common psychiatric GWAS variants operate. The precise molecular mechanism (altered splicing, intronic regulatory element, expression quantitative trait locus) has not been characterized in published literature.

The Evidence

The strongest human-genetic evidence linking rs4395923 to anxiety comes from large-scale GWAS of anxiety-related traits, where this CYP7B1 intronic variant reached association. The neurobiological rationale is strongly supported by mechanistic studies:

The founding Cyp7b neurosteroid study⁷⁷ Cyp7b neurosteroid study
Rose et al. "Cyp7b, a novel brain cytochrome P450, catalyzes the synthesis of neurosteroids 7alpha-hydroxy dehydroepiandrosterone and 7alpha-hydroxy pregnenolone." Proc Natl Acad Sci USA, 1997 established that CYP7B1 is the dominant 7α-hydroxylase in brain tissue, converting DHEA and pregnenolone into inactive triols. The enzyme's broad expression in hippocampus, amygdala, and cortex — regions critical to emotional regulation — positioned it as a neurosteroid gate.

The hippocampal expression study⁸⁸ hippocampal expression study
Yau et al. "Dehydroepiandrosterone 7-hydroxylase CYP7B: predominant expression in primate hippocampus and reduced expression in Alzheimer's disease." Neuroscience, 2003 demonstrated that CYP7B1 is the primary neurosteroid-catabolizing enzyme in primate hippocampus. Its 50% reduction in Alzheimer's disease suggests the enzyme's activity directly shapes local neurosteroid concentrations, with downstream effects on GABA-A receptor tone.

On the GABAergic side, allopregnanolone mediates anxiolysis⁹⁹ allopregnanolone mediates anxiolysis
Antonoudiou et al. "Allopregnanolone Mediates Affective Switching Through Modulation of Oscillatory States in the Basolateral Amygdala." Biol Psychiatry, 2022 through δ-subunit-containing GABA-A receptors in the basolateral amygdala, the brain's threat-detection hub. This tonic inhibitory pathway is precisely what CYP7B1 regulates by controlling substrate availability upstream.

The clinical validation of this pathway comes from FDA-approved neurosteroid drugs: brexanolone and zuranolone¹⁰¹⁰ brexanolone and zuranolone
Both approved by the FDA for postpartum depression; zuranolone is oral, brexanolone is IV-administered are synthetic allopregnanolone analogs that activate GABA-A receptors. Their efficacy confirms that the DHEA → allopregnanolone → GABA-A axis is a modifiable target for mood and anxiety disorders.

The evidence level is emerging: the GWAS signal links the variant to anxiety, and the mechanistic biology is well-established, but no functional studies have directly characterized the effect of rs4395923 on CYP7B1 expression or enzyme activity.

Practical Actions

Because CYP7B1 activity governs local neurosteroid concentrations, and these neurosteroids tonically modulate GABAergic inhibition, the actionable implications differ based on whether CYP7B1 activity is likely increased or decreased by the variant. Carriers of the A risk allele appear to have altered CYP7B1 function that shifts the neurosteroid equilibrium, which can be partially modulated through factors that influence DHEA levels and conversion rates — including stress management through specific non-generic means (e.g., sauna exposure has documented effects on DHEA), supplemental DHEA or pregnenolone (with medical oversight), and avoidance of compounds that suppress GABA-A signaling.

Interactions

CYP7B1 sits upstream of the progesterone → pregnenolone → allopregnanolone conversion chain, which also involves AKR1C enzymes (AKR1C1-4) and 5α-reductase (SRD5A1/SRD5A2). Variants in these downstream enzymes would interact with rs4395923 to determine final allopregnanolone concentrations. Additionally, CYP19A1 (aromatase) and CYP17A1 variants in the adrenal androgen synthesis pathway influence baseline DHEA availability, the substrate CYP7B1 acts upon. Estrogen status (estrogen receptor variants, menopause) strongly modulates CYP7B1 expression via ERβ — making gene-environment interactions with hormonal transitions particularly relevant.

Interleukin-6 (IL-6) is one of the body's most powerful inflammatory messengers. When tissue is damaged, infected, or metabolically stressed, IL-6 floods the bloodstream, triggering C-reactive protein (CRP) production in the liver, activating immune cells, and — at chronically elevated levels — accelerating atherosclerosis and contributing to cardiovascular disease. The IL6R gene encodes the interleukin-6 receptor (IL-6R)¹¹ interleukin-6 receptor (IL-6R)
the cell-surface protein that binds IL-6 and initiates downstream JAK-STAT3 signaling cascades. A soluble form of this receptor (sIL-6R), shed from cell surfaces, enables "trans-signaling" — extending IL-6 activity to cells that do not themselves express membrane-bound IL-6R. rs4537545 is an intronic variant in IL6R whose C allele tags a haplotype associated with elevated inflammatory and lipid markers, and reduced protection from coronary heart disease.

The Mechanism

rs4537545 sits within intron 9 of IL6R on chromosome 1q21 and does not itself change the receptor's amino acid sequence. Its cardiovascular significance comes from linkage disequilibrium (LD)²² linkage disequilibrium (LD)
a statistical association between nearby genetic variants, meaning they are inherited together more often than chance would predict with the functional coding variant rs2228145 (Asp358Ala, p.Asp358Ala). The Asp358Ala substitution in the membrane-proximal domain of IL-6R alters the cleavage efficiency of the receptor's ectodomain by the metalloprotease ADAM17 (TACE), increasing release of sIL-6R into circulation. Higher circulating sIL-6R amplifies IL-6 trans-signaling in tissues that lack membrane-bound IL-6R — including vascular smooth muscle and endothelial cells — while paradoxically reducing classic IL-6 signaling in hepatocytes, which lowers CRP and fibrinogen production.

The rs4845625*T / rs4537545*C haplotype represents the pro-inflammatory configuration: reduced Asp358Ala activity, less sIL-6R shedding, stronger hepatic classic IL-6 signaling, and consequently higher circulating CRP and LDL cholesterol.

The Evidence

The most powerful evidence linking IL6R variants to cardiovascular disease comes from a Mendelian randomization meta-analysis coordinated by the IL6R MR Consortium³³ meta-analysis coordinated by the IL6R MR Consortium
Swerdlow DI et al., Lancet 2012, which combined data from 40 studies (up to 133,449 individuals for biomarker endpoints) and 25,458 coronary heart disease (CHD) cases alongside 100,740 controls across 25 studies. The Asp358Ala allele (tagged by rs4537545 through LD) was associated with a 9.45% increase in circulating IL-6 per allele (95% CI 8.34–10.57), an 8.35% decrease in CRP per allele (95% CI 7.31–9.38), and a 0.85% decrease in fibrinogen per allele — alongside a per-allele CHD odds ratio of 0.95 (95% CI 0.93–0.97, p=1.53×10⁻⁵). This inverse relationship — higher IL-6, lower CRP — reflects the sIL-6R shedding mechanism shifting IL-6 activity away from hepatic acute-phase protein synthesis. The genetic evidence parallels clinical trial findings for IL-6R-blocking biologics (tocilizumab, sarilumab), supporting IL-6R signaling as a causal cardiovascular target.

The specific haplotype containing rs4537545*C was directly linked to cardiovascular biomarker risk in a study by Arguinano et al.⁴⁴ study by Arguinano et al.
Arguinano AA et al., Genes Immun 2017, which examined two IL6R SNPs in French and Dutch cohorts. The rs4845625*T/rs4537545*C haplotype was simultaneously associated with elevated CRP (P=0.009), higher LDL-C (P=0.007), and elevated ApoB (P=0.009) — the full atherogenic triad. The rs4537545 T allele alone showed inverse associations with CRP (P=0.009), while the combination of risk alleles at both loci amplified the biomarker effect beyond either SNP alone.

In a prospective cohort of 559 Danish patients with severe chronic heart failure⁵⁵ 559 Danish patients with severe chronic heart failure
Hansen PR et al., Pharmacogenomics J 2019, IL6R pathway SNPs — including rs4537545 and the functionally linked rs2228145 — were among independent predictors of cardiovascular death and all-cause mortality over a mean 5-year follow-up (14-year observation window). Heterozygous carriers of related IL6R variants showed hazard ratios of 1.37–1.39 for cardiovascular death (p < 0.008), pointing to the prognostic importance of IL-6 signaling genetics in established heart disease.

Practical Actions

For individuals carrying the CC genotype, the actionable priorities are monitoring inflammatory cardiovascular biomarkers (hs-CRP and LDL-C), since this genotype is associated with higher baseline levels of both. Omega-3 fatty acids at pharmacological doses reduce CRP, and high-sensitivity statin trials show reductions in both CRP and cardiovascular events even at baseline LDL levels that clinical guidelines would not normally treat.

For individuals on IL-6R-targeting biologics (tocilizumab or sarilumab) for rheumatoid arthritis or other indications, IL6R genotype may influence receptor sensitivity and treatment response — a clinically relevant pharmacogenomic consideration to discuss with a prescriber.

Interactions

rs4537545 is in LD with rs2228145 (the Asp358Ala coding variant) and rs8192284, which have been the primary variants studied in GWAS and Mendelian randomization analyses. The rs4845625 variant shows strong haplotypic interaction with rs4537545: the combination of rs4845625*T and rs4537545*C produces a larger simultaneous effect on CRP, LDL-C, and ApoB than either variant alone, suggesting that IL6R haplotype-level analysis captures more cardiovascular risk than individual SNPs. Individuals who carry rs4537545*C alongside rs4845625*T represent the highest-risk configuration for these inflammatory and lipid biomarkers. Interaction with the CRP gene variants (rs1205, rs1800947) may further modulate baseline CRP levels beyond the IL6R pathway contribution.

SMAD3 is the central intracellular signal transducer of TGF-beta (transforming growth factor-beta)¹¹ TGF-beta (transforming growth factor-beta)
A pleiotropic cytokine that governs immune tolerance, Treg differentiation, and mucosal homeostasis; when TGF-beta binds its receptor, SMAD2 and SMAD3 are phosphorylated and translocate to the nucleus to regulate target genes, the master pathway governing regulatory T cell (Treg) differentiation and immune tolerance. In immune cells, SMAD3 is required for Foxp3 expression — the transcription factor that defines Tregs — and for restraining both Th2 (allergic) and Th17 (autoimmune mucosal) lineages. rs4562997 is a second intronic enhancer variant in SMAD3, located at chromosome 15q22.33 (position 67,165,814 on GRCh38), roughly 15.5 kilobases downstream from the first confirmed enhancer variant, rs17293632. Together they constitute two independently validated regulatory control points for SMAD3 expression in immune-relevant tissues.

The Mechanism

Functional luciferase reporter assays²² Functional luciferase reporter assays
Reporter assays in which the variant sequence drives expression of a luminescent protein, enabling direct quantification of allele-specific transcriptional activity in thyroid cancer cell lines (TPC-1 and BCPAP) confirmed that both rs4562997 and rs17293632 regulate SMAD3 transcription through allele-specific enhancer elements located within SMAD3 introns. The two enhancers act independently — each drives SMAD3 expression based on the allele present at that position — meaning the combined haplotype state of both variants determines the net SMAD3 expression level in cells where these enhancers are active. While the Wang et al. 2018 study was conducted in the context of thyroid cancer susceptibility at the 15q22 locus, the enhancer regulatory mechanism is cell-type and context dependent: the same enhancer elements are active in immune cells, where SMAD3 expression governs Treg competency. Both alleles at rs4562997 produce measurably different transcriptional outputs (p<0.01 to p<0.001 in reporter assays), confirming the variant is not a passenger polymorphism but a true functional regulatory element.

The SMAD3 locus at 15q22 has been fine-mapped in IBD GWAS³³ fine-mapped in IBD GWAS
Fine-mapping identifies the most likely causal variant(s) within an associated region by computing posterior probabilities across all variants in strong LD to two independent association signals, consistent with the existence of at least two functional regulatory variants in this region. This dual-signal architecture maps precisely to the two confirmed enhancers at rs17293632 and rs4562997.

The Evidence

The Ferreira et al. 2017 Nature Genetics study⁴⁴ Ferreira et al. 2017 Nature Genetics study of 360,838 participants identified the SMAD3 locus as one of 136 genome-wide significant risk loci for allergic disease, with pleiotropic effects across asthma, hay fever, and eczema. The same locus appears in Crohn's disease GWAS by Franke et al. 2010⁵⁵ Crohn's disease GWAS by Franke et al. 2010 in a meta-analysis of six datasets (6,333 cases, 15,056 controls discovery phase; 29,720 replication), confirming SMAD3 among 71 established Crohn's susceptibility genes. This dual appearance in both allergic and autoimmune GWAS is the hallmark of the immune tolerance axis: SMAD3 impairment allows both Th2 (allergic) and Th17 (mucosal autoimmune) responses to escape restraint.

For the partner variant rs17293632, O'Donnell et al. 2019⁶⁶ O'Donnell et al. 2019 in a North American Crohn's cohort of 1,495 patients found that SMAD3 was among eight susceptibility variants associated with accelerated progression to abdominal surgery (P<0.05), suggesting SMAD3 functional status influences disease course, not just susceptibility. The Brylak et al. 2025 pediatric IBD study⁷⁷ Brylak et al. 2025 pediatric IBD study in 286 Polish children observed SMAD3 genotype-associated differences in corticosteroid requirements in Crohn's disease. rs4562997 is the second functional variant contributing to the same regulatory program, and individuals carrying risk alleles at both enhancer positions are expected to have more substantially reduced SMAD3 expression than either variant alone would predict. Direct clinical outcome data specific to rs4562997 are not yet available independently of rs17293632.

Practical Actions

The A allele at rs4562997 marks reduced SMAD3 enhancer activity at this second regulatory element. As with rs17293632, the clinical consequence is not deterministic — most carriers remain disease-free — but the allele reduces SMAD3-mediated immune tolerance capacity, lowering the threshold for both allergic sensitization and mucosal inflammation. The gut microbiome is the most tractable environmental modifier: short-chain fatty acids (SCFAs) from fiber fermentation, particularly butyrate, reinforce Foxp3+ Treg differentiation through SMAD3-dependent pathways and can partially compensate for reduced baseline SMAD3 enhancer activity. Fiber diversity (30+ plant species per week) predicts microbiome richness and SCFA production more reliably than total fiber quantity alone.

Carriers of the AA genotype who also carry the rs17293632 T allele face compounding SMAD3 expression reduction across two independent enhancers — the combined haplotype effect is likely greater than either variant alone, warranting more proactive gut health monitoring.

Interactions

rs4562997 and rs17293632 are both confirmed allele-specific SMAD3 enhancers located within the same gene, ~15.5 kb apart. Their combined haplotype state determines net SMAD3 expression in enhancer-active tissues, including immune cells. Carriers of risk alleles at both positions (A at rs4562997, T at rs17293632) may have more substantially impaired TGF-beta–SMAD3 signaling than either variant predicts individually. The SMAD3 pathway also intersects with IL-10 (rs1800795) signaling — IL-10 cooperates with TGF-beta for mucosal tolerance — so risk alleles in both pathways compound gut mucosal vulnerability.

The TNFAIP3 gene on chromosome 6q23 encodes A20, the primary negative regulator of NF-κB inflammatory signaling¹¹ A20, the primary negative regulator of NF-κB inflammatory signaling
A20 is a ubiquitin-editing enzyme that terminates immune activation by deubiquitinating key signaling proteins; TNFAIP3 stands for TNF Alpha Induced Protein 3. The 6q23 locus is one of the most replicated autoimmune susceptibility regions in the human genome, carrying three independently inherited risk signals that each contribute to RA and SLE susceptibility through distinct mechanisms. rs5029937 is the third and most proximally located of these signals — it sits within intron 2 of TNFAIP3 itself, in a separate linkage disequilibrium block from the intergenic variants rs6920220 and rs10499194 that lie approximately 150 kb upstream. The T allele, rare in Europeans (~3%) but substantially more common in African populations (~27%), marks a haplotype associated with elevated autoimmune disease risk, and individuals who carry it alongside the risk alleles at the upstream intergenic SNPs face the steepest combined risk at this locus.

The Mechanism

rs5029937 resides in a 71 kb LD block that is structurally distinct from the intergenic LD block containing rs6920220 and rs10499194. Its location within intron 2 of TNFAIP3 places it in a region that could influence pre-mRNA splicing, intronic regulatory elements, or enhancer activity within the gene body. The precise functional mechanism has not been resolved — like many intronic GWAS signals, rs5029937 may be a proxy for an unidentified causal variant within the same haplotype rather than directly functional itself. What is established is that it is statistically independent of the two upstream intergenic signals: conditional logistic regression²² conditional logistic regression
After conditioning on both rs6920220 and rs13207033 in multiple independent datasets, rs5029937 retained significant association with P=0.02, and combining WTCCC data showed P values reaching 4.71×10⁻¹¹ — well into genome-wide significance territory.

The downstream functional consequence is presumed to impair A20-mediated NF-κB termination, consistent with the two upstream signals that reduce A20 transcription (rs6920220) and enzymatic activity (rs2230926 F127C). Whether rs5029937 impairs A20 expression, splicing efficiency, or interacts with intronic regulatory sequences that modulate tissue-specific expression remains under investigation.

The variant shows a notable association pattern by autoantibody status³³ autoantibody status
rs5029937 was strongly associated with RF-positive and anti-CCP-positive RA cases but not with anti-CCP-negative RA in the original discovery cohort, mirroring the biology of seropositive disease where NF-κB-driven autoantibody production plays a larger role.

The Evidence

The variant was identified as one of three independent signals at 6q23 in an analysis that applied conditional logistic regression to map the locus structure. The key three-signal paper by Orozco et al. (2009) established that when rs5029937 T allele carriers also carry the rs6920220 A allele and lack the rs10499194 protective T allele, the combined odds ratio reaches 1.86⁴⁴ combined odds ratio reaches 1.86
4.4% of RA patients versus 2.3% of controls carried this highest-risk haplotype combination at 6q23. This represents one of the clearest examples of multiple independent risk signals at a single locus acting additively to substantially amplify RA susceptibility beyond any individual signal's contribution.

The RA association was originally identified in a meta-analysis and imputation study at the TNFAIP3 locus⁵⁵ meta-analysis and imputation study at the TNFAIP3 locus
Bates JS et al. 2009 — identified a 109 kb risk haplotype spanning the TNFAIP3 region, with rs5029937 among the contributing markers using European populations.

Beyond RA, rs5029937 shows broader autoimmune pleiotropism consistent with A20's role across the immune system. A meta-analysis of 18,501 SLE patients and 30,435 controls⁶⁶ meta-analysis of 18,501 SLE patients and 30,435 controls
Zhang MY et al. 2016 — pooled ORs with 95% CI across 23 studies testing TNFAIP3 polymorphisms including rs5029937, rs2230926, rs5029939, and rs3757173 found significant SLE association (P<0.001) in both European and Asian populations. A Korean case-control study⁷⁷ Korean case-control study
133 SLE patients vs 422 healthy controls; Kim SK et al. Rheumatology 2014 found rs5029937 T allele conferred OR 2.13 (95% CI 1.25–3.65, P=0.02) for SLE, while interestingly not showing significant RA association in the same cohort — echoing the population-specific and disease-specific LD patterns seen across the 6q23 locus.

A population-level RA study from Iran found the T allele associated with RA with OR 2.61 for the allele comparison (95% CI 1.38–4.92, P=0.004), and the combined TT+GT genotype versus GG showed OR 3.46 (95% CI 1.49–8.08). While this was a small cohort (50 cases/50 controls), the effect direction is consistent with European discovery data.

The T allele is very rare in Europeans (~3%) and essentially absent in some East Asian populations (dbSNP ALFA data: 0% in the small East Asian sample), while reaching ~27% frequency in African populations and ~7% in Latino populations. This population stratification has important implications: the locus likely contributes more substantially to autoimmune disease burden in African ancestry populations than European GWAS samples suggest, and population-specific LD patterns may shift the disease-relevant haplotype tagging across populations.

The VITAL randomized controlled trial⁸⁸ VITAL randomized controlled trial
25,871 participants randomized to vitamin D3 2000 IU/day, omega-3 1g/day, or placebo, followed for 5 years is the most directly actionable intervention evidence for NF-κB pathway modulation: vitamin D reduced incident autoimmune disease by 22% (HR 0.78, P=0.05) and omega-3 reduced by 15%, with benefits persisting two years after supplementation ended. These interventions act on the NF-κB pathway that TNFAIP3/A20 regulates.

Interactions

rs5029937 is the third leg of the three-signal 6q23 locus model. The complete risk hierarchy at this locus requires integrating all three signals: rs6920220 (intergenic, reduces A20 transcription), rs10499194/rs13207033 (intergenic, protective haplotype when T allele present), and rs5029937 (intronic, risk when T allele present). Carriers of both risk signals (rs6920220 A allele and rs5029937 T allele) while lacking the protective allele at rs10499194 face the maximum 6q23 combined OR of 1.86.

The TNFAIP3 missense variant rs2230926 (F127C) impairs A20 catalytic activity through a completely distinct mechanism. Carriers of rs5029937 T allele who also carry rs2230926 G allele may face compounded A20 dysfunction — the intronic variant potentially reducing expression or splicing efficiency while the missense variant reduces enzymatic function.

PTPN22 R620W (rs2476601) intersects with TNFAIP3 in seropositive autoimmune disease risk: PTPN22 lowers T-cell activation thresholds while TNFAIP3 variants prolong NF-κB inflammatory signaling. The combination of rs5029937 T allele and PTPN22 risk allele may be particularly consequential for seropositive RA risk given both variants' preferential association with RF/anti-CCP-positive disease.

Von Willebrand factor (VWF) is a large glycoprotein that serves two essential roles in hemostasis: it acts as molecular glue that tethers platelets to damaged blood vessel walls, and it escorts coagulation factor VIII through the circulation, protecting it from premature breakdown. Without adequate VWF, even a minor cut or dental procedure can trigger prolonged, difficult-to-control bleeding. The VWF R1853X variant introduces a premature stop codon that truncates the protein at position 1853, eliminating its ability to form the large multimeric structures needed for normal platelet adhesion.

The Mechanism

The VWF gene on chromosome 12 is transcribed from the minus (coding) strand. On the plus strand, the pathogenic change is G→A at position 6,013,544 (GRCh38), which corresponds to a CGA→TGA (Arg→Stop) substitution in codon 1853 of the mature protein. This stop-gained variant¹¹ stop-gained variant
Also called a nonsense mutation; a single base change that converts an amino acid codon into a stop signal, prematurely terminating translation truncates VWF before its C-terminal cystine knot domain, which is essential for dimerization and multimerization. Without intact multimerization, the resulting protein cannot assemble into the ultra-large VWF multimers that are most effective at capturing platelets under high shear flow in arteries and arterioles. In homozygous individuals, essentially no functional VWF is produced, causing von Willebrand disease type 3²² von Willebrand disease type 3
The most severe form of VWD, characterized by near-complete absence of VWF antigen and activity, plus secondary factor VIII deficiency.

The Evidence

The R1853X variant was first documented by Zhang et al. in 1992³³ first documented by Zhang et al. in 1992
Performed at Karolinska Hospital, Stockholm; the study identified nonsense mutations at CGA codons in exons 28, 32, and 45 of the VWF gene in 25 Swedish patients with severe type 3 VWD. The research showed that homozygous carriers exhibited a pronounced bleeding tendency consistent with type 3 disease, while heterozygous relatives showed the milder type 1 phenotype — establishing the codominant dose-response relationship between allele count and disease severity.

The variant was subsequently confirmed as pathogenic in the ThromboGenomics project⁴⁴ ThromboGenomics project
High-throughput sequencing of 2,396 patients with rare hemostatic disorders at University of Cambridge; identified the variant in a European individual through the 3WINTERS-IPS registry. Classification applied ACMG 2015 criteria with PVS1 (null variant in a gene where loss of function is a known disease mechanism), meeting pathogenic threshold.

Type 3 VWD caused by biallelic VWF null mutations is characterized by: VWF antigen below 1 IU/dL (reference ≥50), VWF ristocetin cofactor activity undetectable, and factor VIII activity typically 1–10% of normal due to the loss of VWF's carrier and stabilizing function. Clinically, this produces spontaneous mucosal bleeding (epistaxis, gingival bleeding, menorrhagia), gastrointestinal hemorrhage, and in severe cases joint bleeding (hemarthrosis) resembling hemophilia A — unlike milder VWD types which rarely cause joint bleeds.

Global allele frequency of the A (stop) allele is approximately 0.014% (1 in 7,000 alleles) across gnomAD datasets, making homozygosity (type 3 VWD) vanishingly rare at roughly 1 in 200 million births if Hardy-Weinberg equilibrium holds — consistent with the observed prevalence of severe VWD of about 1 in 1,000,000 in the general population.

Practical Actions

Management depends critically on genotype. Heterozygous carriers (type 1 VWD) have mildly reduced VWF levels and typically require treatment only at hemostatic challenges — surgery, dental procedures, childbirth. [Desmopressin (DDAVP) | A synthetic analog of antidiuretic hormone that causes endothelial cells to release stored VWF; effective in type 1 but not type 3 VWD] can temporarily raise VWF levels 3- to 5-fold in responsive carriers, but its utility in heterozygotes carrying a null allele must be confirmed by a DDAVP challenge test, since approximately 25% of type 1 carriers are non-responsive.

Homozygous R1853X carriers (type 3 VWD) are DDAVP non-responsive — there is no stored VWF to release — and require plasma-derived or recombinant VWF concentrate for any bleeding episode or surgical procedure. The target for treatment is VWF:RCo ≥50 IU/dL (activity) and FVIII ≥50 IU/dL for surgical procedures. Prophylactic VWF concentrate infusions (1-2 times weekly) are used in patients with frequent spontaneous bleeds, particularly joint bleeds.

Interactions

The severity of VWD in R1853X heterozygotes can be modified by blood group ABO — individuals with blood group O have VWF levels roughly 25% lower than non-O individuals, and an O-group R1853X heterozygote may have sufficiently low VWF to present with more severe type 1 phenotype than expected from the single variant alone. This interaction warrants complete VWD panel testing including ABO-adjusted reference ranges.

Compound heterozygosity — carrying R1853X on one chromosome and a different VWF pathogenic variant on the other — produces a type 3-like phenotype even without R1853X homozygosity. Family members of R1853X carriers should therefore be tested not only for R1853X but for the full VWF coding sequence if a severe phenotype is present.